The first treatment for post-Covid-19 exposure consists of a cocktail of two monoclonal antibodies, casirivimab and imdevimab. This monoclonal treatment has been administered to many patients infected with the SARS-CoV-2 virus to help the immune system fight the disease and prevent hospitalizations. Many hospitals are already overwhelmed, and this cocktail infusion can be the answer to help the medical system.
REGEN-COV treatment: the answer to preventing hospitalization
This week the Governor of Texas, Greg Abbott, tested positive for the new coronavirus and is isolated at the Governor’s Mansion. The first lady tested negative. The press release from his office announced that Abbott is receiving monoclonal antibody treatment and that his breakthrough infection is under control. Although fully vaccinated people can get infected with the SARS-CoV-2 virus, most experience no symptoms or just mild ones. The monoclonal treatment can be the additional help to put an end to the pandemic.
Who can receive the treatment?
Regeneron Company announced that the treatment can be used by those 12 or older exposed to the virus or who tested positive. The data provided shows that the treatment reduces the risk of symptomatic infection of those who have been in close contact with an infected person. Moreover, it is also efficient as a post-exposure treatment. The FDA issued emergency authorization for the monoclonal cocktail from Regeneron, and many people have benefited from it.
Doctors believe that this therapy is the best treatment available because it helps block the virus from entering the human cells. The duration of administration is around 21 minutes, followed by an hour of monitoring. On August 4, Texas required nine additional infusion centers to administer the treatment. The trailers would be used across the state to help ease the burden of overcrowded hospitals.
Health providers are the only ones that can decide if the patient should receive the REGEN-COV monoclonal antibody treatment.